Core One Labs Inc. (OTCQB: CLABF) (CSE:COOL)(Frankfurt:LD6), (WKN:A3CSSU) announced that it is in discussions with several pharmaceutical laboratories and research organizations to supply them with active pharmaceutical ingredient psilocybin to meet their psychedelic research needs.
Scientific interest in psilocybin has grown exponentially in recent years, with many high profile clinical trials showing enormous potential for the psychedelic compound in treating various mental health and neurological disorders, such as anxiety, depression, obsessive-compulsive disorder, various addictions, as well as Alzheimer's and Parkinson's diseases, to name a few. Promising results from many of these trials, though still in early stages and requiring further study, have given rise to rapid growth of …